Hinge Health Short Sellers Retreat as Peers Face Pressure

HNGE enters its November 5 earnings report with short sellers pulling back sharply even as most of its closest peers face a rougher week.

Among the correlated group, HIMS dropped 8.5% over the past week, NUTX fell 11.2%, and OMDA shed 7.2%. HNGE moved in the opposite direction, gaining 3.4% to close at $115.48. Short interest, at 14.5% of free float, remains one of the higher readings in the group. But the direction matters here: that position shrank 17.5% in a single week, one of the sharper retreats since late September when shares were trading closer to $90.

The unwinding short position has coincided with a dramatic loosening of the borrow market. Availability now exceeds 3,000% of short interest, meaning there are roughly 30 shares available to borrow for every one already lent out. One week ago that ratio was below 900%. Cost to borrow has edged down to 0.54%, low by any measure, though it has tripled from its level a month ago. The direction of short covering, not forced by any squeeze, looks more like conviction-driven exit than a technical unwind. One parallel worth noting: in mid-October, when short interest briefly peaked above 6.9 million shares, the ORTEX short score touched 54.9. It has since retreated to 45.6, consistent with the covering trend.

Options positioning has grown more cautious even as shorts have left. The put/call ratio climbed to 0.71 on November 2, well above its 20-day average of 0.53 and about 1.2 standard deviations above the norm. Put demand has been building steadily through October from a ratio below 0.35 in late September. The 52-week range on this measure runs from 0.27 to 1.86, so current positioning is defensive but not extreme. The clearest interpretation is that a portion of the market is buying protection rather than building outright short positions, a different expression of the same caution.

The analyst community has moved consistently in one direction into this print. Multiple firms raised targets in October, with Stifel lifting to $130 and Keybanc moving to $140, both maintaining positive ratings. Barclays was more restrained at $110. The mean consensus target of $114.31 is roughly in line with the current price, which compresses the implied upside compared with where targets stood before the stock's 18% rally this past month. The bull case rests on 3Q26 download growth of 59% year on year, win rates above 80%, and a 2026 calculated billings guide of $960 to $970 million. The bear case centres on execution risk: the business depends on enterprise renewals, performance guarantees, and consistent platform investment in a competitive MSK landscape where any renewal slip hits revenue quickly. A separate data point worth tracking: retail attention, measured by Wikipedia views and ORTEX page traffic, is running at a z-score of 2.3 above the prior 90-day average, the highest in the observable window.

Insider activity has been net negative over the past 90 days, with a net disposal of roughly $92.6 million in share value. Most of the selling came from director Gabriel Mecklenburg, who offloaded more than $20 million in shares on October 12, all under pre-arranged 10b5-1 plans. Pre-planned sales carry less signal than discretionary ones. The CFO's November 1 transaction was a tax-withholding transaction, not an open-market sale. BlackRock added 2.66 million shares in the most recent reported period, a notable accumulation for a stock still under two years old as a public company.

The November 5 print will test whether the growth metrics that drove the 18% October rally, download momentum, billings visibility, and enterprise win rates, hold against a margin profile the market is now pricing at a PE above 39 and a price-to-book above 18.